The occurrence of residual or recurrent squamous cell carcinomas in organ transplant recipients after curettage and electrodesiccation.
BACKGROUND
Organ transplant recipients frequently develop multiple squamous cell carcinomas (SCCs). Surgical excision and Mohs micrographic surgery are frequently used treatments for these carcinomas; however, curettage and electrodesiccation are a useful alternative in these patients.


OBJECTIVE
To evaluate the efficacy of curettage and electrodesiccation for the treatment of appropriately selected low-risk SCCs in organ transplant recipients at different sites.


METHODS
Between April 1989 and December 2004, 211 SCCs in 48 organ transplant recipients were treated by curettage and electrodesiccation. Only histologically confirmed SCCs were considered in this study. The charts of these patients were retrospectively reviewed and checked for the rate of residual or recurrent SCCs. The occurrence of residual or recurrent SCCs at different locations after treatment of SCCs with curettage and electrodesiccation was estimated with Kaplan-Meier survival analysis.


RESULTS
The mean follow-up time after curettage and electrodesiccation of the individual SCCs was 50 months (median 41; range 3-186). In total, 13 residual or recurrent SCCs were observed in 10 patients. The overall rate of residual or recurrent SCCs was 6%, with 7% for SCCs on the dorsum of the hands or fingers, 11% for SCCs on the head and neck, 0% for the forearms, and 5% for the remaining nonsun-exposed areas (shoulder, legs). No major clinical or cosmetic adverse events were registered after treatment.


CONCLUSIONS
In organ transplant recipients with many SCCs curettage and electrodesiccation can be a safe therapy for appropriately selected low-risk SCCs, with an acceptable cure rate.
de Graaf
Y G L
YG
Department of Dermatology, Leiden University Medical Centre, the Netherlands. y.g.l.de_graaf@lumc.nl
Basdew
V R
VR
van Zwan-Kralt
N
N
Willemze
R
R
Bavinck
J N Bouwes
JN
D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000473:pathology / Q000601:surgery*; D003475:Curettage; D004598:Electrosurgery; D004812:Epidemiologic Methods; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual; D016377:Organ Transplantation; D012008:Recurrence; D012878:Skin Neoplasms / Q000276:immunology / Q000473:pathology / Q000601:surgery*; D016896:Treatment Outcome